Brissot, EoliaLabopin, MyriamBeckers, Marielle M.Socié, GérardRambaldi, AlessandroVolin, LiisaFinke, JürgenLenhoff, StigKröger, NicolausOssenkoppele, Gert J.Craddock, Charles F.Yakoub-Agha, IbrahimGürman, GünhanRussell, Nigel H.Aljurf, MahmoudPotter, Michael N.Nagler, ArnonOttmann, OliverCornelissen, Jan J.Esteve Reyner, JordiMohty, Mohamad2016-11-252016-11-252015-030390-6078https://hdl.handle.net/2445/104191This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. This retrospective analysis from the EBMT Acute Leukemia Working Party included 473 de novo Philadelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using a human leukocyte antigen-identical sibling or human leukocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred and ninety patients received tyrosine kinase inhibitors before transplant, 329 at induction and 274 at consolidation. Kaplan-Meier estimates of leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at five years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=0.04) and was associated with lower relapse incidence (HR=0.5; P=0.01). In the post-transplant period, multivariate analysis identified prophylactic tyrosine-kinase inhibitor administration to be a significant factor for improved leukemia-free survival (HR=0.44; P=0.002) and overall survival (HR=0.42; P=0.004), and a lower relapse incidence (HR=0.40; P=0.01). Over the past decade, administration of tyrosine kinase inhibitors before allogeneic stem cell transplantation has significantly improved the long-term allogeneic stem cell transplantation outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further confirm the potential benefit of the prophylactic use of tyrosine kinase inhibitors in the post-transplant setting.8 p.application/pdfeng(c) Ferrata Storti Foundation, 2015Leucèmia limfocítica crònicaCèl·lules mareInhibidors enzimàticsChronic lymphocytic leukemiaStem cellsEnzyme inhibitorsinfo:eu-repo/semantics/article6635022016-11-25info:eu-repo/semantics/openAccess25527562